188 related articles for article (PubMed ID: 35641210)
1. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
Nardi V; McAfee SL; Dal Cin P; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Foster J; Fathi AT; Hock H
Oncologist; 2022 Mar; 27(2):82-86. PubMed ID: 35641210
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
4. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
5. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
6. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
7. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
8. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
[TBL] [Abstract][Full Text] [Related]
9. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon PA; Cools J; Gilliland DG; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2008 Jun; 22(6):1117-24. PubMed ID: 18401417
[TBL] [Abstract][Full Text] [Related]
10. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
11. A Cryptic NUP214-ABL1 Fusion in B-cell Precursor Acute Lymphoblastic Leukemia.
Tsujimoto SI; Nakano Y; Osumi T; Okada K; Ouchi-Uchiyama M; Kataoka K; Fujii Y; Ohki K; Seki M; Tamagawa N; Takita J; Ogawa S; Kiyokawa N; Hara J; Kato M
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e397-e399. PubMed ID: 29219890
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and
Chen Y; Zhang L; Huang J; Hong X; Zhao J; Wang Z; Zhang K
Exp Ther Med; 2017 Nov; 14(5):3979-3984. PubMed ID: 29067094
[TBL] [Abstract][Full Text] [Related]
13. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.
Kurita D; Hatta Y; Hojo A; Kura Y; Sawada U; Kanda Y; Takei M
Cancer Genet; 2016 Apr; 209(4):161-5. PubMed ID: 26854094
[TBL] [Abstract][Full Text] [Related]
14. ABL1 fusions in T-cell acute lymphoblastic leukemia.
De Keersmaecker K
Verh K Acad Geneeskd Belg; 2008; 70(4):245-55. PubMed ID: 19166098
[TBL] [Abstract][Full Text] [Related]
15.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
17. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance.
Ballerini P; Busson M; Fasola S; van den Akker J; Lapillonne H; Romana SP; Marynen P; Bernard OA; Landman-Parker J; Berger R
Leukemia; 2005 Mar; 19(3):468-70. PubMed ID: 15674415
[No Abstract] [Full Text] [Related]
18. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
Chiaretti S; Tavolaro S; Ghia EM; Ariola C; Matteucci C; Elia L; Maggio R; Messina M; Ricciardi MR; Vitale A; Ritz J; Mecucci C; Guarini A; Foà R
Haematologica; 2007 May; 92(5):619-26. PubMed ID: 17488685
[TBL] [Abstract][Full Text] [Related]
19. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
Iacobucci I; Roberts KG
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.
Nardi V; Ku N; Frigault MJ; Dubuc AM; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Burke ME; Foster J; Dal Cin P; Maus MV; Fathi AT; Hock H
Blood Adv; 2020 Jan; 4(1):106-111. PubMed ID: 31905241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]